LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 64

Search options

  1. Article ; Online: Editorial: Global Health Concerns as Vaccine-Preventable Infections Including SARS-CoV-2 (JN.1), Influenza, Respiratory Syncytial Virus (RSV), and Measles Continue to Rise.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 30, Page(s) e943911

    Abstract: In December 2023, the US Centers for Disease Control and Prevention (CDC) published the updated 2024 Advisory Committee on Immunization Practices (ACIP) Adult Immunization Schedule, which is available online for access by the public and healthcare ... ...

    Abstract In December 2023, the US Centers for Disease Control and Prevention (CDC) published the updated 2024 Advisory Committee on Immunization Practices (ACIP) Adult Immunization Schedule, which is available online for access by the public and healthcare professionals. These new guidelines come at a time when the incidence of vaccine-preventable viral infections from SARS-CoV-2 (JN.1), respiratory syncytial virus (RSV), influenza, and measles are increasing in adults and children due to vaccine hesitancy, or non-compliance. This editorial aims to highlight the ongoing global health concerns for the consequences of increasing reports of vaccine-preventable infections, including SARS-CoV-2 (JN.1), influenza, RSV, and measles, to understand the causes of vaccine hesitancy, and introduce some public health measures that could improve vaccine uptake.
    MeSH term(s) Child ; Adult ; Humans ; Influenza, Human/epidemiology ; SARS-CoV-2 ; Respiratory Syncytial Viruses ; Global Health ; COVID-19/prevention & control ; Influenza Vaccines ; Measles/epidemiology ; Measles/prevention & control ; Communicable Diseases
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.943911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Editorial: Climate Change and the Spread of Vector-Borne Diseases, Including Dengue, Malaria, Lyme Disease, and West Nile Virus Infection.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 29, Page(s) e943546

    Abstract: The major health threats from climate change include increasing temperatures, air pollution, extreme weather events, changes in the spread of infectious diseases, antimicrobial resistance, emerging pathogens, and an increase in vector-borne disease. ... ...

    Abstract The major health threats from climate change include increasing temperatures, air pollution, extreme weather events, changes in the spread of infectious diseases, antimicrobial resistance, emerging pathogens, and an increase in vector-borne disease. Between October and December 2023, in 200 medical journal, epidemiologists, clinicians, healthcare policymakers, and journal editors published an emergency call to action to health professionals, the United Nations, and political leaders on climate change and its effects on the ecosystem and human health. Also, in December 2023, the Intergovernmental Panel on Climate Change (IPCC) published its sixth Assessment Report (AR6) that summarizes current knowledge, impacts, and health risks from climate change, as well as suggestions for mitigation and adaptation. For over a decade, the IPCC has reported that the prevalence of vector-borne diseases has increased and highlighted the importance of monitoring dengue, malaria, Lyme disease, West Nile virus infection, and other vector-borne diseases. This editorial aims to provide an update on the association between climate change and the spread of vector-borne diseases and highlights the urgent need for public health and disease prevention and treatment strategies to control the rise in vector-borne diseases.
    MeSH term(s) Humans ; Climate Change ; West Nile Fever/epidemiology ; Ecosystem ; Malaria/epidemiology ; Vector Borne Diseases ; Lyme Disease/epidemiology ; Dengue/epidemiology
    Language English
    Publishing date 2024-01-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.943546
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 30, Page(s) e943912

    Abstract: The clinical association of purpura, arthralgia, and arthritis was first described in 1837 in a publication by Johann Lukas Schönlein, a German physician. In 1874, Eduard Henoch, a student of Schönlein, reported cases of children with purpura, abdominal ... ...

    Abstract The clinical association of purpura, arthralgia, and arthritis was first described in 1837 in a publication by Johann Lukas Schönlein, a German physician. In 1874, Eduard Henoch, a student of Schönlein, reported cases of children with purpura, abdominal pain, bloody diarrhea, and joint pain. IgA vasculitis, or Henoch-Schönlein purpura, is a systemic hypersensitivity vasculitis caused by the deposition of immune complexes in small blood vessels, including the renal glomeruli and mesangium. In the skin, the presentation is with non-thrombocytopenic purpura or urticaria. Worldwide, IgA nephropathy is the most common cause of primary glomerulonephritis. Detection of IgA deposition in small blood vessels and the renal glomeruli is diagnostic in most cases. This article aims to review the history, current classification, epidemiology, presentation, and diagnosis of IgA vasculitis and nephropathy, disease associations or trigger factors, including infections, vaccines, and therapeutic agents, and highlights some future approaches to improve diagnosis and clinical management.
    MeSH term(s) Child ; Humans ; IgA Vasculitis/diagnosis ; IgA Vasculitis/drug therapy ; Immunoglobulin A/therapeutic use ; Glomerulonephritis, IGA/diagnosis ; Glomerulonephritis, IGA/complications ; Vasculitis/diagnosis ; Kidney Glomerulus ; Hypersensitivity
    Chemical Substances Immunoglobulin A
    Language English
    Publishing date 2024-01-28
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.943912
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 30, Page(s) e944204

    Abstract: In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for their research on the endonuclease, clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-associated protein 9 (CRISPR-Cas9) ... ...

    Abstract In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for their research on the endonuclease, clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-associated protein 9 (CRISPR-Cas9) method for DNA editing. On 16 November 2023, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was the first to approve the CRISPR-Cas9 gene editing therapy, Casgevy (exagamglogene autotemcel), for the treatment of patients with transfusion-dependent b-thalassemia and the treatment of sickle cell disease in patients aged ≥12 years with recurrent vaso-occlusive crises. On 8 December 2023, the US Food and Drug Administration (FDA) approved both Casgevy and Lyfgenia (lovotibeglogene autotemcel) for patients with sickle cell disease. On 15 December 2023, the European Medicines Agency (EMA) approved Casgevy for sickle cell disease and transfusion-dependent ß-thalassemia. This Editorial aims to present an update on the landmark first regulatory approvals of CRISPR-Cas9 for patients with sickle cell disease and transfusion-dependent b-thalassemia and the potential challenges for therapeutic gene (DNA) editing.
    MeSH term(s) United States ; Humans ; Gene Editing/methods ; CRISPR-Cas Systems/genetics ; beta-Thalassemia/genetics ; beta-Thalassemia/therapy ; Anemia, Sickle Cell/genetics ; Anemia, Sickle Cell/therapy ; DNA
    Chemical Substances DNA (9007-49-2)
    Language English
    Publishing date 2024-03-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.944204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 30, Page(s) e944436

    Abstract: On 22 February 2024, the World Health Organization (WHO) stated that, following the recent resurgence of measles cases in Europe, more than half the world's countries could expect significant measles outbreaks this year. Measles is a highly infectious ... ...

    Abstract On 22 February 2024, the World Health Organization (WHO) stated that, following the recent resurgence of measles cases in Europe, more than half the world's countries could expect significant measles outbreaks this year. Measles is a highly infectious virus with a primary case reproduction number (R0) of 12-18. Measles infection can be severe, resulting in pneumonia, and also more rarely in subacute sclerosing panencephalitis (SSPE), which occurs in 1 child out of every 1,000 and can be fatal. Until the 1990s, the hope of eliminating measles seemed possible following the successful development of effective vaccines, given individually or in the combined measles, mumps, and rubella (MMR) vaccine. Vaccine hesitancy due to misinformation about possible vaccine side effects, reduced vaccine uptake during and after the COVID-19 pandemic, and lack of awareness of the severe consequences of measles infection have contributed to low vaccine uptake, resulting in vulnerable communities. This article aims to review the recent resurgence of measles cases in the US, Europe, and the UK, to provide a reminder of the potential severity of measles, and to consider the causes of the failure to eliminate this vaccine-preventable viral infection.
    MeSH term(s) Child ; Humans ; Measles-Mumps-Rubella Vaccine/therapeutic use ; Vaccine-Preventable Diseases/chemically induced ; Vaccine-Preventable Diseases/epidemiology ; Pandemics ; Vaccination ; Measles/epidemiology ; Measles/prevention & control
    Chemical Substances Measles-Mumps-Rubella Vaccine
    Language English
    Publishing date 2024-03-13
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.944436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection - Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2024  Volume 30, Page(s) e944600

    Abstract: In April 1984, 40 years ago, the Secretary of the US Department of Health and Human Services announced that Dr. Robert Gallo and his colleagues at the National Cancer Institute (NCI) had confirmed the cause of acquired immunodeficiency syndrome (AIDS) as ...

    Abstract In April 1984, 40 years ago, the Secretary of the US Department of Health and Human Services announced that Dr. Robert Gallo and his colleagues at the National Cancer Institute (NCI) had confirmed the cause of acquired immunodeficiency syndrome (AIDS) as a retrovirus, which became known as human immunodeficiency virus (HIV) in 1986. For the past 40 years, prevention and cure of HIV infection have been the dual 'holy grail' sought but still not achieved. By the beginning of 2024, the World Health Organization (WHO) estimated that in the past 40 years, between 65.0 million and 113.0 million people have been infected with HIV, and between 32.9 million and 51.3 million people have died from HIV infection. On 29 February 2024, the WHO published an updated report in response to increasing reports of HIV drug resistance (HIVDR). Currently, HIV vaccines in development are in early-stage clinical trials. People with HIV are more likely to develop tuberculosis, with increasing rates of antimicrobial resistance. MTBVAC is the first live attenuated vaccine to prevent Mycobacterium tuberculosis infection, with phase 2a safety and efficacy clinical trial data expected at the end of 2024. This editorial aims to summarize the current challenges and hopes for developing vaccines to prevent HIV infection and approaches to overcome antiretroviral drug resistance as a cure for HIV/AIDS.
    MeSH term(s) Humans ; Acquired Immunodeficiency Syndrome/drug therapy ; Acquired Immunodeficiency Syndrome/prevention & control ; HIV Infections/drug therapy ; HIV Infections/prevention & control ; Longitudinal Studies ; Tuberculosis ; Vaccine Development ; Clinical Trials as Topic
    Language English
    Publishing date 2024-04-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.944600
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2023  Volume 29, Page(s) e942672

    Abstract: The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report includes relevant topics from the clinician's perspective and evidence published on chronic obstructive pulmonary disease (COPD) since GOLD 2017. The World Health Organization ( ...

    Abstract The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report includes relevant topics from the clinician's perspective and evidence published on chronic obstructive pulmonary disease (COPD) since GOLD 2017. The World Health Organization (WHO) and GOLD 2023 have developed an updated definition of COPD as, "a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration, exacerbations) due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction." GOLD 2023 includes recommendations for COPD patients diagnosed with COVID-19 and acknowledges the role of reduced air quality in the etiology and progression of COPD. In May 2023, the GOLD Scientific Committee on Air Pollution and COPD reported that air pollution increasingly contributes to the pathogenesis of COPD. This Editorial aims to introduce the updated GOLD 2023 report in the context of climate change and the aftermath of the COVID-19 pandemic.
    MeSH term(s) Humans ; Climate Change ; Pandemics ; COVID-19 ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Air Pollution/adverse effects
    Language English
    Publishing date 2023-10-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.942672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2023  Volume 29, Page(s) e942960

    Abstract: On May 5, 2023, the Director-General of the World Health Organization (WHO) advised the transition to long-term management of the COVID-19 pandemic and that COVID-19 is now an established and ongoing health issue that is no longer a public health ... ...

    Abstract On May 5, 2023, the Director-General of the World Health Organization (WHO) advised the transition to long-term management of the COVID-19 pandemic and that COVID-19 is now an established and ongoing health issue that is no longer a public health emergency of international concern (PHEIC). The WHO decision was based on an analysis of the decreasing trend in mortality, the decline in hospital admissions and Intensive Care Unit (ICU) admissions from COVID-19, and the increasing levels of population immunity to SARS-CoV-2. This Editorial aims to highlight what is known of the factors that drive new variants, subvariants, and lineages of SARS-CoV-2 associated with immune escape to previous infection or vaccines and resistance to antiviral treatments as the end of the COVID-19 pandemic is declared.
    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19 ; Pandemics ; Hospitalization ; Antiviral Agents
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2023-11-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.942960
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory Infections.

    Parums, Dinah V

    Medical science monitor : international medical journal of experimental and clinical research

    2023  Volume 29, Page(s) e943312

    Abstract: In October and November 2023, hospitals in the major cities of Beijing and Liaoning in northern China reported a surge in cases of pneumonia in children, with some hospitals being overwhelmed by pediatric emergency admissions. Similar outbreaks of ... ...

    Abstract In October and November 2023, hospitals in the major cities of Beijing and Liaoning in northern China reported a surge in cases of pneumonia in children, with some hospitals being overwhelmed by pediatric emergency admissions. Similar outbreaks of childhood pneumonia had been reported in the autumn of 2022 in Europe and North America. Therefore, increased reports of childhood pneumonia could be driven by post-pandemic changes in the pathogenesis of endemic respiratory infections other than COVID-19, including Mycoplasma pneumoniae, respiratory syncytial virus (RSV), and influenza, rather than emerging novel pathogens. However, the recent reports of increased hospitalizations for children with pneumonia warrant continued infection surveillance and monitoring to exclude new respiratory pathogens or more virulent variants of known pathogens, including SARS-CoV-2. This editorial aims to present what is known about the re-emergence of endemic respiratory infections, which may be the cause of the recently reported outbreaks of childhood pneumonia.
    MeSH term(s) Humans ; Child ; Pandemics ; Respiratory Tract Infections/epidemiology ; Pneumonia/epidemiology ; Respiratory Syncytial Virus, Human ; Influenza, Human/epidemiology
    Language English
    Publishing date 2023-12-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 1439041-3
    ISSN 1643-3750 ; 1234-1010
    ISSN (online) 1643-3750
    ISSN 1234-1010
    DOI 10.12659/MSM.943312
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Editorial: The Increasing Relevance of Case Reports in Medical Education and Clinical Practice - and How to Write Them.

    Parums, Dinah V

    The American journal of case reports

    2023  Volume 24, Page(s) e942670

    Abstract: Between 2012 and 2022, the American Journal of Case Reports published over 3,500 case reports and case series. In 2022-23, this journal achieved an impact factor (IF) of 1.2. The significant merits of published case reports include identifying rare ... ...

    Abstract Between 2012 and 2022, the American Journal of Case Reports published over 3,500 case reports and case series. In 2022-23, this journal achieved an impact factor (IF) of 1.2. The significant merits of published case reports include identifying rare diseases and syndromes, treatment complications or side effects, pharmacovigilance, and medical education. The limitations or cautions of the case report include the inability to generalize, the lack of establishment of a cause-effect relationship, and over-interpretation. Historically, new clinical conditions and syndromes have been identified. Since 2020, the COVID-19 pandemic has significantly impacted manuscript submissions and publications, as illustrated for this journal. This editorial aims to highlight the importance of case reports and series, recent publication trends and includes recommendations on what to do and what not to do when preparing and writing the manuscript for a case report.
    MeSH term(s) Humans ; Pandemics ; Writing ; Education, Medical
    Language English
    Publishing date 2023-10-01
    Publishing country United States
    Document type Case Reports ; Editorial
    ZDB-ID 2517183-5
    ISSN 1941-5923 ; 1941-5923
    ISSN (online) 1941-5923
    ISSN 1941-5923
    DOI 10.12659/AJCR.942670
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top